AGEN - Agenus Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.495
+0.015 (+0.43%)
As of 12:08PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close3.480
Open3.470
Bid3.510 x 1200
Ask3.520 x 2200
Day's Range3.430 - 3.520
52 Week Range3.060 - 6.190
Volume185,389
Avg. Volume1,611,798
Market Cap363.476M
Beta2.91
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • PR Newswire7 days ago

    Agenus to Present Clinical Data on Lead Programs at ASCO 2018

    - AGEN1884 (CTLA-4) and AGEN2034 (PD-1) show objective clinical responses - More than 100 patients treated with AGEN1884 and AGEN2034 - Combination trial has commenced in cervical cancer LEXINGTON, Mass. ...

  • PR Newswire17 days ago

    Agenus to Present at Deutsche Bank's 43rd Annual Health Care Conference in Boston

    LEXINGTON, Mass. , May 7 , 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , ...

  • PR Newswire17 days ago

    Agenus Reports First Quarter 2018 Financial Results and Provides Corporate Update

    Agenus to host conference call and webcast today at 11am ET LEXINGTON, Mass. , May 7, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint ...

  • ACCESSWIRE17 days ago

    Agenus Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 7, 2018 / Agenus Inc. (NASDAQ: AGEN ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 7, 2018 at 11:00 AM Eastern Time. To listen to ...

  • PR Newswire21 days ago

    Agenus to Report First Quarter 2018 Financial Results on May 7, 2018 and Host Conference Call and Webcast

    LEXINGTON, Mass. , May 3, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , will ...

  • AgenTus Therapeutics to Present on Novel TCR Platform and Progress at PEGS Summit in Boston, MA
    PR Newswire23 days ago

    AgenTus Therapeutics to Present on Novel TCR Platform and Progress at PEGS Summit in Boston, MA

    LEXINGTON, Mass. , May 1, 2018 /PRNewswire/ -- AgenTus Therapeutics, a subsidiary of Agenus Inc. (NASDAQ: AGEN), dedicated to advancing breakthrough "living drugs" for potentially curative treatments ...

  • PR Newswirelast month

    Three Agenus Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) 2018 Annual Meeting

    LEXINGTON, Mass. , April 11 , 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that three ...

  • PR Newswire2 months ago

    Agenus to Present at Healthcare Investor Conferences In April

    LEXINGTON, Mass., March 29, 2018 /PRNewswire/ -- Agenus Inc. (AGEN), an immune-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced today that members of the Company's leadership will present and host one-on-one meetings at two healthcare investment conferences in April. Jennifer Buell, Ph.D., Chief External Affairs and Communications Officer of Agenus, will present on Agenus and AgenTus at the Jefferies IO Cell Therapy Summit on April 3, 2018, at the Boston Harbor Hotel, Boston, Massachusetts. Corporate presentation is at 7:55 a.m. ET.

  • PR Newswire2 months ago

    Agenus Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update

    LEXINGTON, Mass. , March 15, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, provided a corporate update ...

  • ACCESSWIRE2 months ago

    Agenus Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 15, 2018 / Agenus Inc. (NASDAQ: AGEN ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 15, 2018 at 11:00 AM Eastern Time. To listen ...

  • PR Newswire3 months ago

    Agenus to Report Fourth Quarter and Full Year 2017 Financial Results on March 15, 2018 and Host Conference Call and Webcast

    LEXINGTON, Mass. , March 7, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, will release its fourth quarter ...

  • PR Newswire4 months ago

    Agenus Announces Combination Clinical Trials of its Anti-CTLA4 (AGEN1884) & Anti-PD1 (AGEN2034)

    LEXINGTON, Mass., Jan. 22, 2018 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the launch of its combination trial with its proprietary anti-CTLA4 (AGEN1884) and anti-PD1 (AGEN2034) antibodies. This Phase 1/2 clinical trial launched in December 2017 and enrollment into the first cohort has been rapidly completed. The optimal combination dose and schedule will be evaluated in an expansion cohort of patients with inoperable cervical cancer who have relapsed after platinum-containing chemotherapy. In addition, we believe both agents are crucial for combinations with our portfolio of proprietary immune oncology therapeutics," said Garo Armen, Ph.D., Chairman and CEO of Agenus.

  • PR Newswire4 months ago

    Agenus Inc. Closes $230 Million Royalty Monetization with HealthCare Royalty Partners

    LEXINGTON, Mass. , Jan. 22, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the closing ...

  • PR Newswire4 months ago

    Agenus Inc. Announces $230 Million Royalty Monetization with HealthCare Royalty Partners

    LEXINGTON, Mass., Jan. 8, 2018 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced a $230 million non-dilutive royalty transaction with HealthCare Royalty Partners (HCR). The transaction is comprised of $190 million of cash proceeds at closing plus up to $40 million in milestone payments. Agenus will use part of these proceeds to redeem its royalty bond from Oberland and the additional monies to advance its registrational studies with anti-CTLA-4 and anti-PD-1 for planned BLA filings in 2019 and 2020.

  • PR Newswire5 months ago

    Agenus' Dr. John Castle Joins Thought Leadership Panel on I-O Combinations at 10th Annual Biotech Showcase 2018

    LEXINGTON, Mass., Jan. 4, 2018 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that Dr. John Castle, Head of Translational Medicine and Bioinformatics, will participate in a panel entitled "IO on the Move: New Targets, New Trends, New Combinations" on Wednesday, January 10,, 2018 at 9:00-10:00 am P.T. at the 10th Annual Biotech Showcase™ at the Hilton San Francisco Union Square. Dr. John Castle is a pioneer in translational bioinformatics and genomics and leader in the identification of immune-inducing antigens for cancer therapy.

  • PR Newswire5 months ago

    Agenus Announces Key Leadership to Advance Combination Trials For Planned BLA Filings

    -- Hagop Youssoufian, MD, named Senior Clinical Strategist -- John Castle, Ph.D., appointed as Head of Translational Medicine and Bioinformatics -- Tyler Curiel, MD, MPH named Senior Strategist for Translational ...

  • ACCESSWIRE6 months ago

    Today’s Research Reports on Stocks to Watch: Ampio Pharmaceuticals and Agenus Inc.

    NEW YORK, NY / ACCESSWIRE / November 24, 2017 / Shares of Ampio blew up on Wednesday after encouraging data was published in a peer review journal about its Ampion serum that is being developed to treat ...

  • PR Newswire6 months ago

    Agenus Receives License Fee of $4 Million USD from Merck

    LEXINGTON, Mass., Nov. 15, 2017 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the receipt of a $4 million payment for the advancement of an undisclosed antibody under the license and research collaboration agreement with Merck, known as MSD outside the United States and Canada. As previously announced, Merck is responsible for all future product development expenses for the selected antibody and Agenus is eligible to receive up to an additional $99 million in milestone payments, as well as royalties on worldwide product sales. "We are very pleased with the progress of our collaboration with Merck and the advancement of this antibody towards the clinic," said Garo Armen, Ph.D. Chairman and CEO of Agenus.

  • PR Newswire6 months ago

    Agenus To Present on Lead Antibody Programs AGEN1884 (CTLA-4) and AGEN2034 (PD-1) at SITC 2017

    LEXINGTON, Mass., Nov. 9, 2017 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced that data on AGEN1884 (CTLA-4) and AGEN2034 (PD-1) demonstrated that the molecules achieved the desired pharmacologic function and combination synergy will be presented at the Society for Immunotherapy of Cancer's (SITC) 31st Annual Meeting, Nov. 9-13th.  Agenus recently announced the launch of three clinical programs with these lead antibodies designed as potential pivotal programs to support BLA filings as soon as 2H 2019.  These milestones are additional evidence of Agenus delivering against its I-O strategy.

  • PR Newswire6 months ago

    Agenus to Present at the Jefferies Global Healthcare Conference in London

    LEXINGTON, Mass., Nov. 8, 2017 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced today that Jennifer Buell, Ph.D., Chief Communications and External Affairs Officer at Agenus, and Michael Plater, Ph.D., Chief Business Officer, Agenus, will make a presentation and host one-on one meetings with investors at the Jefferies Global Healthcare Conference at the Waldorf Hilton in London, U.K. on Wednesday, November 15, 2017.  The Company's presentation will take place at 8:00 a.m. GMT.

  • PR Newswire7 months ago

    Agenus Reports Third Quarter 2017 Financial Results and Provides Corporate Update

    Agenus to host conference call and webcast today at 11am ET LEXINGTON, Mass. , Nov. 7, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint ...

  • ACCESSWIRE7 months ago

    Agenus Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / November 7, 2017 / Agenus Inc. (NASDAQ: AGEN ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 7, 2017 at 11:00 AM Eastern Time. To ...

  • PR Newswire7 months ago

    Agenus to Report Third Quarter 2017 Financial Results on November 7, 2017 and Host Conference Call and Webcast

    LEXINGTON, Mass., Oct. 26, 2017 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, will release its third quarter 2017 financial results before the market opens on Tuesday, November 7, 2017. Agenus executives will host a conference call and webcast at 11:00 a.m. ET the same day. The call will also be webcast and will be accessible from the Company's website at http://investor.agenusbio.com/presentation-webcasts or with this link https://www.webcaster4.com/Webcast/Page/1556/23075.